Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VOR, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Telitacicept | Generalized Myasthenia Gravis | Phase 3 · NCT06456580 | Recruiting |
| Allogeneic Anti-CD33 CAR T-cells VCAR33 | Leukemia, Myeloid, Acute | Phase 1/2 · NCT05984199 | Terminated |
| Tremtelectogene Empogeditemcel (VOR33) | Leukemia, Myeloid, Acute | Phase 1/2 · NCT04849910 | Terminated |
Also used in these trials (approved or third-party drugs, not VOR's own candidates): Gemtuzumab Ozogamicin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VOR holds $466.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $31.8M/quarter from operations, an estimated runway of 44 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VOR files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VOR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →